CMO growth hampered by innovator approvals from mega cap pharma, yet contract clinical and recombinant vector manufacturing growing in demand
Cambridge, UK, September 29th 2020 - Following on from June's breakthrough news that OKRA hit its target of 2 million validated predictions at >95% accuracy a full 6 months early, the company has set its sights on a record-breaking 6 million predictions completed by year end. This means that pharma companies have benefitted from an unparalleled level of support during the most uncertain time in recent memory, using predictions to guide their staff to take the right next step. This is 1 million more than the revised target set only in June.
Recently, COVAXX announced it would soon enter human trials as the company is focused on rapidly developing a Multitope Peptide-based Vaccine (MPV) against SARS-CoV-2. While the biotech industry is now on a race to develop vaccines to curb COVID-19 pandemics, with several dozen players competing for the future market, COVAXX is a special case that can not be taken lightly.
Not only COVAXX’s new vaccine candidate is constructed off a commercially proven peptide-based vaccine platform by United Biomedical (UBI), a leader with a 30-year history in creating vaccines with over 500 million doses sold annually and 5 billion -- cumulatively in animal health indications for infectious disease that has demonstrated safety and efficacy. But it is also co-founded by two biotech “stars” of modern-day: Peter H. Diamandis, M.D., founder and executive chairman of XPRIZE, executive founder of Singularity University, and a dozen other tech companies, a popular science author; and Mei Mei Hu, co-founder of United Neuroscience, a member of Fortune “40 Under 40” and TIME “100 Next List”.
A preplated library of 16800 compounds designed for the discovery of new SARS-CoV-2 and pan-Coronavirus antivirals
KIEV, Ukraine -- Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), today announced the release of the Coronavirus Library. The new screening library capitalizes on Enamine’s decades of chemical R&D, advanced library design expertise, and experience with creating focused antiviral libraries. Enamine is a participant of a global Open Science initiative “COVID Moonshot”, aimed at discovering novel therapeutics against SARS-CoV-2.
Recently my favorite website ENDPOINTSNEWS published a rating of key players in the ongoing COVID-19 vaccine race. Compared to many vaccine developers with announced initiatives in this space, all the 28 organizations in the ENDPOINTSNEWS list stated at least preliminary positive results of their vaccine programs, and are firmly advancing them towards later stages of development.
By the way, a notorious “Russian vaccine” by The Gamaleya Research Institute of Epidemiology and Microbiology also made its way to this list under the number 6, but I prefer not to touch upon this development. A lot has been said already about this story - to the point, and not so much.
In this post I would rather talk about the number one in the list, a development undeservedly underrated by the media, which however might be the first to actually enter the global SARS-CoV2 vaccine market…